NCT03801434 - Ruxolitinib in Treating Patients with Hypereosinophilic Syndrome or Primary Eosinophilic Disorders | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2019

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

BCR-JAK2 Fusion Protein ExpressionBlasts 20 Percent or Less of Peripheral Blood White CellsBlasts More Than 5 Percent of Bone Marrow Nucleated CellsBlasts More Than 5 Percent of Peripheral Blood White CellsBlasts Under 20 Percent of Bone Marrow Nucleated CellsChronic Eosinophilic Leukemia, Not Otherwise SpecifiedEosinophiliaHepatomegalyHypereosinophilic SyndromeJAK2 Gene MutationSplenomegalyTEL-JAK2 Fusion Protein Expression

Interventions

DRUG

Ruxolitinib

Given PO

Trial Locations (4)

84112

TERMINATED

University of Utah, Salt Lake City

94304

RECRUITING

Stanford Cancer Institute Palo Alto, Palo Alto

97201

TERMINATED

OHSU Knight Cancer Institute, Portland

98109

TERMINATED

Fred Hutchinson cancer research center, Seattle